



In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension. The drug is already approved in several countries for treatment of kidney and liver cancer, and it may be time to consider it for patients suffering from advanced portal hypertension, the authors suggest. Their findings are in the April issue of Hepatology, a journal published by John Wiley and Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience…
A new study pinpoints certain aspects of the immune system that may play a role in the recurrence and progression of hepatitis C virus (HCV) after liver transplantation. The study is in the April issue of Liver Transplantation, a journal published by John Wiley and Sons. The article is also available online at Wiley Interscience…
Gobi Desert yield new species of nut-cracking dinosaur
Bird-like dinosaur tells story of finger evolution